miR-20 Regulated Genes and Pathways as Targets for Therapeutic Intervention
The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-20a, using miR-20a to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.
1 . A method of modulating gene expression in a cell comprising administering to the cell an amount of an isolated nucleic acid comprising a miR-20 nucleic acid sequence in an amount sufficient to modulate the expression of one or more genes identified in Table 1, 3, 4, or 5.
2 . The method of claim 1 , wherein the cell is in a subject having, suspected of having, or at risk of developing a metabolic, an immunologic, an infectious, a cardiovascular, a digestive, an endocrine, an ocular, a genitourinary, a blood, a musculoskeletal, a nervous system, a congenital, a respiratory, a skin, or a cancerous disease or condition.
3 . The method of claim 2 , wherein the infectious disease or condition is a parasitic, bacterial, viral, or fungal infection.
4 . The method of claim 2 , wherein the cancerous condition is astrocytoma, acute myelogenous leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, esophageal squamous cell carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, lipoma, melanoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, lung carcinoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, urothelial carcinoma wherein the modulation of one or more gene is sufficient for a therapeutic response.
5 . The method of claim 1 , wherein the expression of a gene is down-regulated.
6 . The method of claim 1 , wherein the expression of a gene is up-regulated.
7 . The method of claim 1 , wherein the cell is an epithelial, an endothelial, a mesothelial, a stromal, or a mucosal cell.
8 . The method of claim 1 , wherein the cell is a brain, a neuronal, a blood, an esophageal, a lung, a cardiovascular, a liver, a breast, a bone, a thyroid, a glandular, an adrenal, a pancreatic, a stomach, a intestinal, a kidney, a bladder, a prostate, a uterus, an ovarian, a testicular, a splenic, a skin, a smooth muscle, a cardiac muscle, a striated muscle cell.
9 . The method of claim 1 , wherein the cell is a cancer cell.
10 . The method of claim 9 , wherein the cancer cell is a neuronal, glial, lung, liver, brain, breast, bladder, blood, leukemic, colon, endometrial, stomach, skin, ovarian, fat, bone, cervical, esophageal, pancreatic, prostate, kidney, or thyroid cell.
11 . The method of claim 1 , wherein the isolated miR-20 nucleic acid is a recombinant nucleic acid.
12 - 16 . (canceled)
17 . The method of claim 1 , wherein the miR-20 nucleic acid is a synthetic nucleic acid.
18 . The method of claim 17 , wherein the nucleic acid is administered at a dose of 0.01 mg/kg of body weight to 10 mg/kg of body weight.
19 . The method of claim 1 , wherein the miR-20 is a hsa-miR-20.
20 . (canceled)
21 . The method of claim 1 , wherein the nucleic acid is administered enterally or parenterally.
22 - 23 . (canceled)
24 . The method of claim 1 , wherein the nucleic acid is comprised in a pharmaceutical formulation.
25 . The method of claim 24 , wherein the pharmaceutical formulation is a lipid composition or a nanoparticle composition.
26 . (canceled)
27 . The method of claim 24 , wherein the pharmaceutical formulation consists of biocompatible and biodegradable molecules.
28 .- 43 . (canceled)
44 . A method of treating a patient diagnosed with or suspected of having or suspected of developing a pathological condition or disease related to a gene modulated by a miRNA comprising the steps of:
(a) administering to the patient an amount of an isolated nucleic acid comprising a miR-20 nucleic acid sequence in an amount sufficient to modulate a cellular pathway or a physiologic pathway; and
(b) administering a second therapy, wherein the modulation of the cellular pathway or physiologic pathway sensitizes the patient to the second therapy.
45 - 49 . (canceled)
50 . A method of assessing a cell, tissue, or subject comprising assessing expression of miR-20 in combination with assessing expression of one or more gene from Table 1, 3, 4, or 5 in at least one sample.
51 . (canceled)